Amylyx Pharma Gains Retail Buzz As Once-Daily Pill Cuts Severe Blood Sugar Crashes In Mid-Stage Trial

Amylyx Pharmaceuticals drew increased retail attention late Sunday after new clinical data presented at ENDO 2025 highlighted the potential of its lead candidate, avexitide, to significantly reduce dangerous blood sugar drops in patients with post-bariatric hypoglycemia (PBH).

In a Phase 2b trial, avexitide 90 mg once daily, the dose being studied in the pivotal Phase 3 Lucidity trial, led to a 64% least-squares mean reduction in the composite rate of Level 2 and Level 3 hypoglycemic events. 

More than half of the participants experienced no severe events during the treatment period.

Avexitide is a treatment being developed for post-bariatric hypoglycemia, a condition that currently has no approved therapies. Backed by FDA Breakthrough Therapy designation, the once-daily pill is designed to block the GLP-1 receptor and help prevent dangerous blood sugar drops. 

New data shared at ENDO 2025 showed that the 90 mg dose maintained steady, around-the-clock activity. 

A Phase 3 study called Lucidity is now underway, with plans to enroll about 75 people who’ve previously undergone gastric bypass surgery. 

Amylyx expects to finish signing up participants in 2025 and release the results in the first half of 2026.

The data and trial momentum come amid fresh bullish coverage from Wall Street. 

Goldman Sachs resumed coverage on Amylyx with a ‘Buy’ rating and $10 price target, citing avexitide’s "blockbuster" potential. 

Guggenheim also started coverage last month with a ‘Buy’ and a $17 target, calling PBH a “not-so-rare” endocrine disease with 50,000–100,000 moderate-to-severe patients in the U.S. 

Citi joined with a ‘Buy’ and $12 target, highlighting multiple late-stage programs and "clear" clinical endpoints across four high-unmet-need indications.

On Stocktwits, retail sentiment for Amylyx was ‘bullish’ amid ‘high’ message volume.

Amylyx’s stock has risen 96.4% so far in 2025.

See also: Crinetics Pharma’s Oral Drug Shows Lasting Relief For Acromegaly Patients In Latest Study; Retail Buzz Builds

For updates and corrections, email newsroom[at]stocktwits[dot]com.